This mechanism may drive rapid tumor growth but also enhances the response of obese patients to PD‐1 checkpoint therapy by reversing macrophage‐induced immunosuppression and increasing T‐cell activity, thereby improving the effectiveness of immunotherapy [16]. Here, PDCD1 is linked to neoplasm.